CEL-SCI Reveals $5.7 Million Offering Price Under NYSE American Guidelines
Cel-SCI Corporation Announces Common Stock Offering Vienna, Virginia, July 11, 2025 – Cel-SCI Corporation, a clinical-stage immunotherapy company for cancer treatment, has revealed a Best Effort pricing initiative to offer 1,500,000 shares of common stock. Each share is priced at $3.82 under NYSE American guidelines. The total revenue from this offering is anticipated to be […]